Diseases, Conditions, Syndromes

First dengue vaccine goes on sale in Guatemala

The world's first vaccine against dengue, a mosquito-borne virus that causes fever and pain and can be fatal, will go on sale in Guatemala within weeks, the French company making it said Tuesday.

Vaccination

Novavax asks EU drug regulator to OK its COVID vaccine

The European Union's drug regulator said it received an application from Novavax to authorize the American biotechnology company's coronavirus vaccine, a request that could significantly boost the continent's vaccine supplies ...

Diseases, Conditions, Syndromes

Dengue vaccine to be tested in India

French health care giant Sanofi Pasteur will soon test a vaccine against dengue fever in India amid concerns about the increasingly global spread of the disease, reports said Monday.

Vaccination

France's Sanofi to invest 2 billion euros in mRNA vaccines

French pharmaceutical giant Sanofi said Tuesday that it would invest 2 billion euros ($2.4 billion) in the mRNA vaccine technology behind the pioneering Covid-19 jabs developed by rivals BioNTech-Pfizer and Moderna.

Pediatrics

Nirsevimab injection cuts RSV-linked infections in preemies

(HealthDay)—Nirsevimab prevents respiratory syncytial virus (RSV)-associated lower respiratory tract infections in healthy preterm infants, while maternal RSV fusion (F) protein nanoparticle vaccination did not meet the ...

Diseases, Conditions, Syndromes

France's Sanofi to work with US Army on Zika vaccine

French pharmaceuticals group Sanofi said Wednesday it would work with the US Army's Walter Reed Institute to develop a potential vaccine against the mosquito-borne Zika virus, linked to brain damage in newborns.

Diseases, Conditions, Syndromes

Sanofi, GSK to start clinical tests of virus vaccine

French pharmaceutical giant Sanofi on Thursday said it would start human trials of the potential coronavirus vaccine it is developing with British peer GSK, following promising preliminary tests.

Medications

Sanofi buys US flu vaccine maker Protein for $750 mln

French pharmaceuticals giant Sanofi, which is looking to boost its presence in biotechnology, said Tuesday it had agreed to buy the privately-owned US vaccines maker Protein Sciences for up to $750 million (658 million euros).

Medications

Doctors Without Borders: snakebite treatment running out

Doctors Without Borders says the world will run out of one of the most effective treatments for snakebites next year, putting the lives of tens of thousands of people at risk, mostly in developing countries.

page 3 from 5